079f2816_BiblioServet__Guidance
[Reference] TA342 [Programme] Technology appraisal guidance [Topic] Inflammatory bowel disease [Guidance] 
Vedolizumab for treating moderately to severely active ulcerative colitis
BiblioServet
Guidance